Physician profile
Peter Buffa
NPI 1790884344
$3,814.98
in general payments reported to CMS, 2019-2025
43 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $346 · 2021: $249 · 2022: $479 · 2023: $186 · 2024: $764 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $415.56 | 2019-2025 | Freestyle Libre 3, Mitraclip, Navitor |
| Lilly USA, LLC | $394.94 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $341.89 | 2022-2025 | |
| Novo Nordisk INC | $294.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.67 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $213.28 | 2019-2024 | Verquvo, Capvaxive, Gardasil |
| Medtronic, INC. | $185.36 | 2024-2025 | Minimed 780g |
| Amarin Pharma, INC. | $170.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $108.09 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Eisai INC. | $104.92 | 2025 | |
| Exact Sciences Corporation | $99.02 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $98.01 | 2024-2025 | Recorlev |
| Janssen Pharmaceuticals, INC | $96.83 | 2019-2025 | Spravato |
| Abbvie INC. | $84.14 | 2020-2025 | |
| Pfizer INC. | $81.70 | 2019-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $80.32 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $71.60 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $66.96 | 2022-2025 | Tepezza, Prolia, Evenity |
| Amneal Pharmaceuticals LLC | $61.32 | 2024 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $59.08 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $50.71 | 2020-2024 | Fasenra, Farxiga |
| Axsome Therapeutics, INC. | $45.83 | 2025 | Auvelity, Symbravo |
| Sanofi Pasteur INC. | $37.80 | 2019-2021 | |
| Beta Bionics, INC. | $36.48 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medicomp INC | $33.50 | 2025 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $32.44 | 2021-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $26.50 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $24.76 | 2025 | Isturisa |
| Teva Pharmaceuticals USA, INC. | $23.97 | 2020 | |
| Allergan, INC. | $23.95 | 2020 | |
| Neurocrine Biosciences, INC. | $23.22 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.69 | 2019 | |
| Daiichi Sankyo INC. | $21.85 | 2021 | |
| Insightec,INC | $19.74 | 2025 | Exablate |
| Ibsa Pharma INC. | $19.04 | 2022 | |
| Insulet Corporation | $16.45 | 2022 | |
| Inspire Medical Systems, INC. | $14.26 | 2025 | Inspire |
| Intuity Medical INC | $13.51 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Spinal Elements, INC. | $12.83 | 2025 | |
| Alnylam Pharmaceuticals INC. | $12.00 | 2022 | |
| Boston Scientific Corporation | $11.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.25 | 2020 | |
| Vivaquant INC, Dba Rhythm Express | $10.37 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Buffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.